CHP
ATXS

Cable Hill Partners’s Astria Therapeutics ATXS Stock Holding History

Cable Hill Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed -$1K – 888
2017
Q4 		$1K Sell
8
-75
-90% -$8.82K ﹤0.01% 896
2017
Q3 		$11K Buy
+83
New +$6.92K 0.01% 543

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cable Hill Partners's ATXS Position: Q1 2018 in Review

Cable Hill Partners sold out of Astria Therapeutics (ATXS) in Q1 2018, closing a stake of 8 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in ATXS in Q3 2017 and held it in 2 quarters. The position peaked at $11K in Q3 2017. 24 funds tracked by Wall St. Rank hold ATXS as of Q1 2018.

  • Cable Hill Partners reported no remaining Astria Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 8 Astria Therapeutics shares in Q1 2018, an estimated $1K.
  • Cable Hill Partners first reported a position in Astria Therapeutics in Q3 2017 and held it in 2 quarters.
  • Cable Hill Partners's Astria Therapeutics position peaked at $11K in Q3 2017.
  • 24 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.